TB--A New Target, a New Drug
- 14 January 2005
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 307 (5707) , 214-215
- https://doi.org/10.1126/science.1108379
Abstract
Tuberculosis (TB) kills 2 million people annually worldwide and imposes huge costs on communities, particularly those in developing countries. Yet no new drugs for TB have been discovered in the past 40 years. This is set to change, as [Cole and Alzari][1] report in their Perspective, with the discovery of a diarylquinoline compound that is highly active against a broad range of mycobacterial species including both the drug-sensitive and drug-resistant forms of M. tuberculosis, the bacterium that causes TB ([ Andries et al .][2]). [1]: http://www.sciencemag.org/cgi/content/full/307/5707/214 [2]: http://www.sciencemag.org/cgi/content/short/307/5707/223Keywords
This publication has 8 references indexed in Scilit:
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Mechanisms of Drug Resistance in Mycobacterium tuberculosisPublished by American Society for Microbiology ,2004
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Mycolactones and Mycobacterium ulcerans diseaseThe Lancet, 2003
- Worldwide Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2002
- Foreword from the Co-Editor-in-ChiefTuberculosis, 2001
- Drug-like properties and the causes of poor solubility and poor permeabilityJournal of Pharmacological and Toxicological Methods, 2000
- Global Burden of TuberculosisJAMA, 1999